Bringing a depth of expertise in product
registration, commercial & business development
Tom Wiggans, former CEO of Dermira, joins as
Executive Chairman
Michael Davin, former CEO of Cynosure, joins
Board of Directors
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the
“Company”) is pleased to note that its Founded Entity, Follica,
today announced the appointment of two veteran biotech executives
to its Board of Directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210114005191/en/
Follica announced the appointment of two
veteran biotech executives to its Board of Directors. Tom Wiggans,
former CEO of Dermira, joins as Executive Chairman, and Michael
Davin, former CEO of Cynosure, joins as an independent member.
Tom Wiggans joins as Executive Chairman with over 30 years of
experience leading biopharmaceutical companies from the start-up
stage to global commercialization. Mr. Wiggans most recently
co-founded and served as Chairman and Chief Executive Officer of
Dermira, a company developing new therapies for chronic skin
conditions. He led the company through two Phase 3 trials that
resulted in U.S. Food and Drug Administration approval of its lead
therapy, Qbrexza®
(glycopyrronium), and the advancement into Phase 3 of its novel
monoclonal antibody for atopic dermatitis. Mr. Wiggans guided
Dermira through Eli Lilly’s acquisition of the company for
approximately $1.1 billion in January of 2020.
Michael Davin joins as an independent member of the Board of
Directors. Mr. Davin brings to Follica over 30 years of experience
in the medical device industry, including 14 years as Chief
Executive Officer at Cynosure, which develops and manufactures
medical and aesthetic treatments for skin revitalization, scar
reduction, hair removal and more. He led the company through an
IPO, international expansion and its acquisition by Hologic, Inc.
for $1.65 billion in 2017.
The full text of the announcement from Follica is as
follows:
Follica Adds Two Leaders in Aesthetic
Medicine and Dermatology to its Board of Directors
Bringing a depth of expertise in product
registration, commercial & business development
Tom Wiggans, former CEO of Dermira, joins as
Executive Chairman
Michael Davin, former CEO of Cynosure, joins
Board of Directors
BOSTON, January 14, 2021 – Follica Inc. (“Follica”), a
biotechnology company developing a regenerative platform designed
to treat androgenetic alopecia, epithelial aging and other related
conditions, today announced the appointment of two veteran biotech
executives to its Board of Directors.
Tom Wiggans joins as Executive Chairman with over 30 years of
experience leading biopharmaceutical companies from the start-up
stage to global commercialization. Mr. Wiggans most recently
co-founded and served as Chairman and Chief Executive Officer of
Dermira, a company developing new therapies for chronic skin
conditions. He led the company through two Phase 3 trials that
resulted in U.S. Food and Drug Administration approval of its lead
therapy, Qbrexza®
(glycopyrronium), and the advancement into Phase 3 of its novel
monoclonal antibody for atopic dermatitis. Mr. Wiggans guided
Dermira through Eli Lilly’s acquisition of the company for
approximately $1.1 billion in January of 2020.
Michael Davin joins as an independent member of the Board of
Directors. Mr. Davin brings to Follica over 30 years of experience
in the medical device industry, including 14 years as Chief
Executive Officer at Cynosure, which develops and manufactures
medical and aesthetic treatments for skin revitalization, scar
reduction, hair removal and more. He led the company through an
IPO, international expansion and its acquisition by Hologic, Inc.
for $1.65 billion in 2017.
“We are very pleased to welcome Tom and Michael to the Follica
board,” said Jason Bhardwaj, Chief Executive Officer of Follica.
“They bring valuable insights in both product and business
development, with particular expertise in dermatology and aesthetic
medicine. This is an exciting time of growth for Follica, as we
prepare to launch a Phase 3 study in male androgenetic alopecia
this year. We look forward to working closely with Tom and Michael
to drive our strategy through this pivotal trial.”
Prior to founding Dermira, Mr. Wiggans served as Chairman of the
Board of Directors and Chief Executive Officer of Peplin, Inc.
until Peplin’s acquisition by LEO Pharma A/S. He has served on the
boards of multiple companies, including Onyx Pharmaceuticals, Inc.
until its acquisition by Amgen. In addition, Mr. Wiggans was
instrumental in the formation of Biotechnology Innovation
Organization (BIO) and served on its Board of Directors for many
years. He is currently on the Board of Directors at Annexon
Biosciences and Forma Therapeutics. He is also a member of the
Board of Trustees of the University of Kansas Endowment
Association. He holds a B.S. in pharmacy from the University of
Kansas and an MBA from Southern Methodist University.
“Follica’s platform has strong potential across several
important indications, including the lead indication androgenetic
alopecia, a condition with tremendous unsatisfied need with
approximately 90 million men and women affected in the United
States alone,” said Mr. Wiggans. “I’m pleased to join the team to
help guide clinical and business strategy through its continued
development of a potential treatment for this condition, which
could have a significant impact for the broad range of individuals
who have long been seeking a more effective approach to growing new
hair.”
Before joining Cynosure, Mr. Davin served as a Co-Founder and
Vice President of Worldwide Sales and Strategic Development of
Cutera, Inc., a provider of laser and other light-based aesthetic
treatment systems. Mr. Davin holds Board of Director positions at
Allurion Technologies, Inkbit Technologies, 15-40 Connection and
OpenTable. He holds a B.S. and B.A. from Southern New Hampshire
University.
“Follica has made excellent progress in advancing a novel
treatment for hair loss, a condition that has serious implications
for both men and women,” said Mr. Davin. “I look forward to working
alongside my fellow board members and the management team as we
advance the program for our first indication and explore the
scientific potential in related conditions.”
About Follica
Follica is a biotechnology company developing a regenerative
platform designed to treat androgenetic alopecia, epithelial aging
and other related conditions. Founded by PureTech Health (LSE:
PRTC, Nasdaq: PRTC), a co-inventor of the current platform, and a
group of world-renowned experts in hair follicle biology and
regenerative medicine, Follica’s experimental treatment platform is
designed to induce an embryonic window via a device with optimized
parameters to initiate hair follicle neogenesis, the formation of
new hair follicles from epithelial (skin) stem cells. This process
is enhanced through the application of a topical compound. Follica
completed a safety and efficacy optimization study in 2019, and its
Phase 3 registration program in male androgenetic alopecia is
expected to begin in 2021. Follica’s technology is based on work
originating from the University of Pennsylvania that has been
further developed by Follica’s internal program. Follica’s
extensive IP portfolio includes IP exclusively licensed from the
University of Pennsylvania as well as Follica-owned IP.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech’s Founded Entities,
as of the date of PureTech’s most recently filed Registration
Statement on Form 20-F, was comprised of 24 products and product
candidates, including two that have received FDA clearance and
European marketing authorization. All of the underlying programs
and platforms that resulted in this pipeline of product candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company’s
unique insights into the biology of the brain, immune and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to our
product candidates and approach towards addressing major diseases,
future prospects, developments, and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks and uncertainties that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, our
expectations regarding the addition of Mr. Wiggans and Mr. Davin to
Follica’s Board of Directors and those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210114005191/en/
Investors
Allison Mead Talbot +1 617 651 3156 amt@puretechhealth.com
U.S. media
Stephanie Simon +1 617 581 9333
stephanie@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024